Find Funding Opportunities

The purpose of this notice is to correct the Application Due Date for NOT-NS-21-068 "HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Advance the Study of Chronic Overlapping Pain Conditions (COPCs)". Applications will be accepted through November 5, 2021, by 5:00PM local time of the applicant organization.

The purpose of this notice is to inform applicants of a change to the Application Types Allowed for RFA-NS-21-010 "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)". The application types have been expanded to include Resubmission applications. This change is effective as of the October 15, 2021 due date.

The purpose of this notice is to inform applicants of a correction to the Letter of Intent (LOI) due date for PAR-22-026 "Selectively Target Technology Development to Understand How Changes or Dysfunction at the Capillary, Arterioles, and Small Lymphatic Vessels Level Can Have Long-term Impact on AD/ADRD (R01 Clinical Trial Not Allowed)". The LOI is due October 8, 2021; this is 30 days prior to the application due date.

Policy notice for BRAIN Initiative PEDP. The BRAIN Initiative will include a new component in most FOAs requiring that applications include a Plan for Enhancing Diverse Perspectives (PEDP) in the proposed research.

The purpose of this notice is to inform interested applicants of a change to the Key Dates for PAR-19-171 "Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)".

This notice informs applicants of an extension to PA-18-937 "Research on Chronic Overlapping Pain Conditions (R01 Clinical Trial Optional)". This Funding Opportunity Announcement (FOA) has been extended by one additional council round. The following New Application due date has been added: February 5, 2022. This FOA will expire May 8, 2022.

This notice informs applications of an extension to PA-18-939 "Research on Chronic Overlapping Pain Conditions (R21 Clinical Trial Not Allowed)". This Funding Opportunity Announcement (FOA) has been extended by one additional council round. The following New Application due date has been added: February 16, 2022. This FOA will expire May 8, 2022.

The purpose of this notice is to provide further clarification of the clinical trials permitted in PAR-20-316 "Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)". This notice is intended to provide more guidance in developing grant applications that are more responsive to the scientific scope of the Funding Opportunity Announcements.

The purpose of this notice is to provide further clarification of the clinical trials permitted in PAR-19-040 "Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)". This notice is intended to provide more guidance in developing grant applications that are more responsive to the scientific scope of the Funding Opportunity Announcements.

The National Institute of Neurological Disorders and Stroke (NINDS) will be hosting an informational webinar on August 17, 2021 from 1PM 2PM (Eastern Time) for all potential applicants interested in these companion Funding Opportunity Announcements (FOAs): RFA-NS-21-009: Creating an Educational Nexus for Training in Experimental Rigor (CENTER) (UC2 Clinical Trial Not Allowed) RFA-NS-21-033: Materials to Enhance Training in Experimental Rigor (METER) (UE5 Clinical Trial Not Allowed) These two FOAs together aim to facilitate teaching of fundamental principles of rigorous biomedical research by developing a new online educational resource for use by a broad range of researchers in an array of learning environments. CENTER will support the establishment of a center to build, evaluate, and disseminate a user-friendly, harmonized, and openly accessible educational resource to promote awareness, understanding, and utilization of the principles of rigorous biomedical research. METER will support the compilation and refinement of the core scholarly content of educational units within this online resource.